Until a few years ago, the quantitative reverse polymerase chain reaction (RT-qPCR) determination of BCR::ABL1 transcript levels was the gold-standard method for monitoring minimal residual disease (MRD) in CML and for the best management of CML patients [17]; nowadays, the limits of RT-qPCR in quantifying BCR::ABL1 transcript levels have been widely reported along with their overcomes via dPCR. The gene discussed is ABL1; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.